拓扑替康联合用药抗肿瘤研究进展

摘要/Abstract

摘要： 恶性肿瘤是世界公认的对人类健康危害最为严重的疾病之一,受到学者的极大关注。拓扑替康(topotecan)属喜树碱类,为拓扑异构酶Ⅰ抑制剂,它能导致DNA复制叉断裂,该作用方式使其不易产生耐药性。拓扑替康主要用于卵巢癌和小细胞肺癌的临床治疗,疗效显著。拓扑替康与多种化合物,如顺铂、索拉菲尼、贝伐单抗、氨柔比星、培美曲塞、吉西他滨等联合使用,均具有一定的抗肿瘤增效作用,因此研究联合应用拓扑替康抗肿瘤的课题值得关注。

关键词: 拓扑替康, 肿瘤, 联合应用

Abstract: Malignant neoplasm threats people’s health seriously and draws wide attention of the scholars. Topotecan (TPT), a topoisonerase inhibitor, can induce the fragmentation of DNA replication fork, therefore it is not easy to produce drug resistance. Also topotecan has been widely and efficiently used in the treatment of ovarian carcinoma and small cell lung carcinoma. TPT has exhibited certain antitumor synergistic effect by combining with a variety of compounds, such as platinum, sorafini, bevacizumab, amrubicin, pemetrexed, gemcitabine. Therefore, it is worthy to investigate the applications of topotecan in combination drug therapy.

Key words: topotecan, tumor, combination drug therapy

中图分类号:

R965

张哲, 孙立, 袁胜涛. 拓扑替康联合用药抗肿瘤研究进展[J]. 中国临床药理学与治疗学, 2015, 20(1): 106-111.

ZHANG Zhe, SUN Li, YUAN Sheng-tao. Progress on researches for topotecan in combination drug therapy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(1): 106-111.

参考文献

[1] 范岚, 谢海棠, 周宏灏. 中西药合用治疗肿瘤的相互作用及其机制探讨[J]. 中国临床药理学与治疗学, 2007, 12(2): 134-139.
[2] Dennis MJ, Beijnen JH. An Overview of the clinical pharmacology of topotecan[J]. Semin Oncol, 1997, 24(Suppl 5): 12-18.
[3] Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond[J]. Nat Rev Cancer, 2006, 6(10): 789-802.
[4] Kaufmann SH, Peereboom D, Buckwalter CA, et al. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines[J]. Nat Cancer Inst, 1996, 88: 734.
[5] Köcher S, Spies-Naumann A, Kriegs M, et al. ATM is required for the repair of Topotecan-induced replication-associated double-strand breaks[J]. Radiother Oncol, 2013, 108(3): 409-414.
[6] Ge XH, Lin Q, Ren XC, et al. Phase II clinical trial of whole-brain irradiation plus three-dimensional conformal boost with concurrent topotecan for brain metastases from lung cancer[J]. Radiat Oncol, 2013, 8(1): 238/1-238/11.
[7] Rodriguez M, Rose PG. Improved therapeutic index of lower dose topotecan chemotherapy in recurrent ovarian cancer[J]. Gynecol Oncol, 2001, 83(2): 257-262.
[8] Nakashio A, Fujita N, Tsuruo T. Topotecan inhibits VEGF- and bFGF-induced vascular endothelial cell migration via downregulation of the PI3K-Akt signaling pathway[J]. Int J Cancer, 2002, 98(1): 36-41.
[9] Calvani M, Rapisarda A, Uranchimeg B, et al. Hypoxic induction of an HIF-1alpha-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells[J]. Blood, 2006, 107(7): 2705-2712.
[10] Zhou LQ, Sun L, Zhu DN, et al. Inhibition of angiogenic activity of hypoxic fibroblast cell line MRC-5 in vitro by topotecan[J]. Med Oncol, 2011, 28(Suppl 1): S653-S659.
[11] Puppo M, Battaglia F, Ottaviano C, et al. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha[J]. Mol Cancer Ther, 2008, 7(7): 1974-1984.
[12] Lin SS, Sun L, Zhang YK, et al. Topotecan inhibits cancer cell migration by down-regulation of chemokine CC motif receptor 7 and matrix metalloproteinases[J]. Acta Pharmacol Sin, 2009, 30(5): 628-636.
[13] Musa F, Blank S, Muggia F. A pharmacokinetic evaluation of topotecan as a cervical cancer therapy[J]. Expert Opin Drug Metab Toxicol, 2013, 9(2): 215-224.
[14] Levy B, Saxena A, Schneider BJ. Systemic therapy for small cell lung cancer[J]. Natl Compr Canc Netw, 2013, 11(7):780-787.
[15] 史惠蓉, 侯丽娟, 乔玉环,等. 顺铂及拓扑替康对卵巢癌裸鼠移植瘤生长的抑制作用[J]. 郑州大学学报, 2004, 39(4): 563-565.
[16] Manci N, Marchetti C, Benedetti Panici P, et al. A prospective phase II study of topotecan (Hycamtin®) and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer[J]. Gynecol Oncol, 2011, 122(2): 285-290.
[17] Rose PG, Sill MW, Fracasso PM, et al. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study[J]. Gynecol Oncol, 2012, 125(1): 158-162.
[18] Hosomi Y, Shibuya M, Watanabe K, et al. Phase II study of topotecan with cisplatin in Japanese patients with small cell lung cancer[J]. Anticancer Res, 2011, 31(10): 3449-3456.
[19] Ramasubbaiah R, Perkins SM, Sutton G, et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group[J]. Gynecol Oncol, 2011, 123(3): 499-504.
[20] Ortholan C, Durivault J, Hannoun-Levi JM, et al. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment[J]. Eur J Cancer, 2010, 46(16): 3022-3036.
[21] McGonigle KF, Muntz HG, Malpass TW, et al. Combined weekly topotecan and biweekly bevacizumab in women with platinum-resistant ovarian, peritoneal, or fallopian tube cancer: results of a phase 2 study[J]. Cancer, 2011, 117(16): 3731-3740.
[22] Powell SF, Beitinjaneh A, Tessema M, et al. Phase II study of topotecan and bevacizumab in advanced, refractory non-small-cell lung cancer[J]. Clin Lung Cancer, 2013, 14(5): 495-501.
[23] Spigel DR, Waterhouse DM, Lane S, et al. Efficacy and safety of oral topotecan and bevacizumab combination as second-line treatment for relapsed small-cell Lung cancer: An open-label multicenter single-arm phase II study[J]. Clin Lung Cancer, 2013, 14(4): 356-363.
[24] Ettinger DS. Amrubicin for the treatment of small cell lung cancer: does effectiveness cross the Pacific[J]. J Thorac Oncol, 2007, 2(2): 160-165.
[25] Jotte R, Conkling P, Reynolds C, et al. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy[J]. J Clin Oncol, 2011, 29(3): 287-293.
[26] Nogami N, Hotta K, Tanimoto M, et al. A phase II study of amrubicin and topotecan combination therapy in patients with relapsed or extensive-disease small-cell lung cancer: Okayama Lung Cancer Study Group Trial 0401[J]. Lung Cancer, 2011, 74(1): 80-84.
[27] Burris HA, Infante JR, Jewell RC, et al. A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies[J]. Oncologist, 2010, 15(9): 954-960.
[28] Serna DS, Bekaii-Saab T, Kraut EH. A phase I study of topotecan and gemcitabine in advanced solid tumors[J]. Invest New Drugs, 2011, 29(6): 1390-1394.
[29] Joly F, Petit T, Pautier P, et al. Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study[J]. Gynecol Oncol, 2009, 115(3): 382-388.
[30] Gupta D, Owers RL, Kim M, et al. A phase II study of weekly topotecan and docetaxel in heavily treated patients with recurrent uterine and ovarian cancers[J]. Gynecol Oncol,2009, 113(3): 327-330.
[31] Qaddoumi I, Billups CA, Tagen M, et al. Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity[J]. Cancer, 2012, 118(22): 5663-5670.
[32] Ashraf K, Shaikh F, Gibson P, et al. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma[J]. Pediatr Blood Cancer, 2013, 60(10): 1636-1641.
[33] Blanchette P, Hogg D, Ferguson P, et al. Topotecan and cyclophosphamide in adults with relapsed sarcoma[J]. Sarcoma, 2012, 2012: 749067.
[34] Kebudi R, Cakir FB, Gorgun O, et al. A modified protocol with vincristine, topotecan, and cyclophosphamide for recurrent/progressive ewing sarcoma family tumors[J]. Pediatr Hematol Oncol, 2013, 30(3): 170-177.
[35] Li N, Song Y, Du P, et al. Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers[J]. Biomed Pharmacother,2013, 67(8): 801-806.
[36] Turner DC, Tillmanns TD, Harstead KE, et al. Combination metronomic oral topotecan and pazopanib: a pharmacokinetic study in patients with gynecological cancer[J]. Anticancer Res, 2013, 33(9): 3823-3829.
[37] Patankar NA, Pritchard J, van Grinsven M, et al. Topotecan and doxorubicin combination to treat recurrent ovarian cancer: the influence of drug exposure time and delivery systems to achieve optimum therapeutic activity[J]. Clin Cancer Res, 2013, 19(4): 865-877.
[38] Kumar S, Mokhtari RB, Oliveira ID, et al. Tumor dynamics in response to antiangiogenic therapy with oral metronomic topotecan and pazopanib in neuroblastoma xenografts[J]. Transl Oncol, 2013, 6(4): 493-503.